Good MorningThe S&P 500 closed the day on Friday with a gain of 0.30% to end at another all-time closing high. The move was driven by a rise in optimism despite the rising number of COVID-19 cases but may be short-lived. While the index moved up to set a new closing high there is still resistance at the all-time intraday high. Until the market moves above that level bullish traders should be cautious.
Next week will bring another round of important economic data that could move the market. Topping the list is the monthly Non-Farm Payroll report and unemployment figures. The risk for the market is that an unexpected uptick in jobless claims in November may point to weaker than expected NFP numbers. Until then there is a raft of other data including the Fed’s Beige Book for investors to consider.
Featured: 5 Stocks Poised to Soar Under Trump's Presidency (Ad) 
|
Stocks | | |
There are different approaches to growing a portfolio. Some investors like to focus on high-flying technology stocks to generate capital appreciation. Others prefer to get their growth in a steadier fashion by investing in companies that have a history of increasing their dividend payments.
Here ... Read the Full Story |
|
From Our PartnersREVEALED: $194 Trillion Trump Market Pattern
Trump fires off a tweet and stocks tank…
He gives a speech and the markets soar…
Now, a new Trump executive order is set to set off a wave worth a potential $194 trillion in the markets.
And Wall Street insider Larry Benedict says it could hand investors who missed out on Trump’s first term a second chance. | | | Click here to discover this exciting new trading pattern. |
|
Markets | | | Asian stock markets were mixed Friday as questions about the effectiveness of one possible coronavirus vaccine weighed on investor optimism.
Benchmarks in Shanghai, Hong Kong and Sydney retreated while Tokyo and Seoul gained.
Investors have been encouraged by reports o... Read the Full Story |
|
Politics | | | Over four decades, Mary Nichols has been the regulator behind some of the nation’s most ambitious climate policies and, in recent years, she’s been their staunchest defender against President Donald Trump's effort to dismantle them.
With Joe Biden heading to the White House, Nichols h... Read the Full Story |
|
From Our PartnersAs you may have seen over the last few weeks, I've been giving out special daily setups on my favorite ticker.
We’ve been taking these setups @ 10AM and so far, we've posted 28 different payouts …
Each of which were delivered at exactly 4PM as the market closed.
You see, these setups require zero oversight and have shown the power to deliver in the most chaotic market conditions.
And after a few weeks of fine-tuning … I knew it was time to let you in on The 4 PM Payout Plan.
That's why Jack Carter and I pulled back the curtain to reveal how we've been able to nail in a 96% win rate in the same window the market lost 11 trillion dollars in value. | | | We also revealed how you can find and execute these setups on your own without any help at all. |
|
Politics | | | North Korean leader Kim Jong Un has ordered at least two people executed, banned fishing at sea and locked down the capital, Pyongyang, as part of frantic efforts to guard against the coronavirus and its economic damage, South Korea’s spy agency told lawmakers Friday.
Kim's government... Read the Full Story |
|
Markets | | | Social media platform Pinterest, Inc. (NYSE: PINS) stock has surprised the markets blowing away analyst expectations even after the heads up from Snapchat (NASDAQ: SNAP) earnings. The platform grew its global users to over 442 million. The visual discovery platform where people post up inspirational... Read the Full Story |
|
From Our PartnersJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%...
Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry." | | | Click here to watch the demo… |
|
Markets | | | Hopes of families for a quick release for six American oil executives detained in Venezuela for three years over an alleged corruption scheme have evaporated, with a judge finding them all guilty and quickly sentencing them to prison Read the Full Story |
|
Healthcare | | | The British government said Friday it has formally asked the country’s medicines regulator to assess whether a coronavirus vaccine developed by AstraZeneca and Oxford University should be authorized for use.
The step comes amid questions about preliminary results from trials of the ja... Read the Full Story |
|
Markets | | |
The Dow hit 30,000 for the first time yesterday and the S&P 500 surged more than 1.6%. But this wasn’t a day where there was green across the board.
Many of yesterday’s winners were companies that have struggled during the pandemic, but expect to turn it around once a vaccine beco... Read the Full Story |
|
Markets | | | Anaplan, Inc; A Small-Cap Tech Growth Story
Anaplan, Inc (NYSE:PLAN) is emerging as a small-cap growth story for 2021 and beyond. The company operates a cloud-based SaaS platform that connects disparate segments of business for planning purposes. This may not sound like much but when it comes to co... Read the Full Story |
|
Markets | | |
For a while now Best Buy (NYSE: BBY), the $30 billion electronics retailer, has been pinned as one of the better-performing retailers in 2020, a year that has forced many to adapt or die. Coming into yesterday’s release, shares were not only up more than 150% since March, but trading at all-... Read the Full Story |
|
The Early Bird Stock Of The Day Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. | | View Today's Stock Pick |
|
